Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab in vitro
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab. Objectives: To test whether low concentrations of rFVIIa could abolish changes in coagulat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925003000 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|